Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

DPH 1,311.00 -2.00 (-0.15%)
price chart
Dechra Pharmaceuticals plc (DPH) Earns "Under Review" Rating from FinnCap
Dechra Pharmaceuticals plc logo Dechra Pharmaceuticals plc (LON:DPH)'s stock had its “under review” rating reaffirmed by stock analysts at FinnCap in a research note issued to investors on Tuesday.
Dechra Pharmaceuticals (LON:DPH) Broker Price Targets  Fiscal Standard
Are RhythmOne plc, Dechra Pharmaceuticals plc and Pagegroup plc 'buys' after ...
Today's update from Pagegroup(LSE: PAGE) shows that the global recruitment company endured a somewhat mixed Q2. While its performance in southern Europe and Benelux was impressive with gross profit growth of 25% and 30% respectively, elsewhere ...
Dechra Pharmaceuticals plc (DPH) Receives Add Rating from Numis Securities Ltd  BBNS
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
OP animal health parent leashes $200M acquisition  Kansas City Business Journal
Should You Buy Dechra Pharmaceuticals plc, Enquest Plc & Cairn Energy PLC Today?
Pet medicines mammoth Dechra Pharmaceuticals (LSE: DPH) cheered the market with terrific half-year numbers in Monday business, propelling the stock 8% higher from the end of last week.
Dechra Pharmaceuticals PLC: Half-Yearly Financial Report 2016
"All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions.
Are GlaxoSmithKline plc, Dechra Pharmaceuticals plc & CareTech Holdings plc On ...
For example, Dechra (LSE: DPH) has been able to increase its earnings at a double-digit rate in each of the last three years, with it rising at an annualised rate of 23% during the period.
Dechra� Pharmaceuticals PLC (Dechra or the Group) : Trading Update
The Board of Dechra Pharmaceuticals PLC (LSE:DPH), issues the following unaudited Trading Update ahead of the Group's half-year financial results for the period ended 31 December 2015, which will be announced on Monday, 22 February 2016.
Should you be buying AstraZeneca plc, Alliance Pharma plc and Dechra ...
One of the major concerns of investors in AstraZeneca (LSE: AZN) in recent years has been its ability to pay dividends. That's because it has been subjected to a patent cliff, where a number of key drugs have come off-patent and with the company ...
International Veterinary Pharmaceutical Business Dechra Pharmaceuticals PLC ...
"During the financial year, we focused on the execution of our strategic priorities. As a result we consolidated our position within the market, invested in the launch of new products and expanded geographically, delivering underlying operating profit ...
Why AstraZeneca plc, Dechra Pharmaceuticals plc And Tissue Regenix Group PLC ...  The Motley Fool UK
Jefferies International reiterated Dechra Pharmaceuticals PLC (LON:DPH) as ...
Dechra Pharmaceuticals PLC is a veterinary pharmaceuticals company. The Company is engaged in the development, manufacture and marketing of products for veterinarians across the world.